[96a5a0]: / output / allTrials / identified / NCT03581773_identified.json

Download this file

381 lines (381 with data), 15.7 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
{
"info": {
"nct_id": "NCT03581773",
"official_title": "FASTERCC: Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy. A Randomized, Double-blind Trial From the Danish Renal Cancer Group (DARENCA Study-4)",
"inclusion_criteria": "1. Patients displaying CTCAE ≥2 mucositis during TKI, mTOR inhibitor or immunotherapy treatment.\n2. Signed written informed consent obtained prior to any study specific procedures.\n3. Patient must be willing and able to comply with the protocol.\n4. Age ≥ 18.\n5. Biopsy proven locally advanced or metastatic renal cell carcinoma.\n6. Females with a negative serum pregnancy test unless childbearing potential can be otherwise excluded (postmenopausal, hysterectomy or oophorectomy) and not lactating.\n7. Fertile women of childbearing potential (<2 years after last menstruation) and men must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgical sterilization).\n8. Karnofsky Performance status ≥ 60%.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "1. Known hypersensitivity to folic acid.\n2. Use of prednisolone more than 10 mg daily.",
"miscellaneous_criteria": "Target population: Patients with inoperable, locally advanced, or metastatic renal cell carcinoma."
},
"inclusion_lines": [
{
"line": "1. Patients displaying CTCAE ≥2 mucositis during TKI, mTOR inhibitor or immunotherapy treatment.",
"criterions": [
{
"exact_snippets": "CTCAE ≥2 mucositis",
"criterion": "mucositis",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">=",
"value": 2,
"unit": "CTCAE"
}
}
]
},
{
"exact_snippets": "during TKI, mTOR inhibitor or immunotherapy treatment",
"criterion": "treatment type",
"requirements": [
{
"requirement_type": "presence",
"expected_value": [
"TKI",
"mTOR inhibitor",
"immunotherapy"
]
}
]
}
]
},
{
"line": "2. Signed written informed consent obtained prior to any study specific procedures.",
"criterions": [
{
"exact_snippets": "Signed written informed consent obtained",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "3. Patient must be willing and able to comply with the protocol.",
"criterions": [
{
"exact_snippets": "Patient must be willing",
"criterion": "willingness to comply with protocol",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "able to comply with the protocol",
"criterion": "ability to comply with protocol",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "4. Age ≥ 18.",
"criterions": [
{
"exact_snippets": "Age ≥ 18",
"criterion": "age",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "5. Biopsy proven locally advanced or metastatic renal cell carcinoma.",
"criterions": [
{
"exact_snippets": "Biopsy proven",
"criterion": "biopsy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "locally advanced",
"criterion": "renal cell carcinoma",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "locally advanced"
}
]
},
{
"exact_snippets": "metastatic renal cell carcinoma",
"criterion": "renal cell carcinoma",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "metastatic"
}
]
}
]
},
{
"line": "6. Females with a negative serum pregnancy test unless childbearing potential can be otherwise excluded (postmenopausal, hysterectomy or oophorectomy) and not lactating.",
"criterions": [
{
"exact_snippets": "Females",
"criterion": "gender",
"requirements": [
{
"requirement_type": "presence",
"expected_value": "female"
}
]
},
{
"exact_snippets": "negative serum pregnancy test",
"criterion": "pregnancy test result",
"requirements": [
{
"requirement_type": "result",
"expected_value": "negative"
}
]
},
{
"exact_snippets": "childbearing potential can be otherwise excluded (postmenopausal, hysterectomy or oophorectomy)",
"criterion": "childbearing potential",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": [
"postmenopausal",
"hysterectomy",
"oophorectomy"
]
}
]
},
{
"exact_snippets": "not lactating",
"criterion": "lactation status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "not lactating"
}
]
}
]
},
{
"line": "7. Fertile women of childbearing potential (<2 years after last menstruation) and men must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgical sterilization).",
"criterions": [
{
"exact_snippets": "Fertile women of childbearing potential (<2 years after last menstruation)",
"criterion": "fertility status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "fertile"
},
{
"requirement_type": "childbearing potential",
"expected_value": true
},
{
"requirement_type": "time since last menstruation",
"expected_value": {
"operator": "<",
"value": 2,
"unit": "years"
}
}
]
},
{
"exact_snippets": "men must use effective means of contraception",
"criterion": "contraception use",
"requirements": [
{
"requirement_type": "gender",
"expected_value": "men"
},
{
"requirement_type": "contraception use",
"expected_value": true
}
]
},
{
"exact_snippets": "women ... must use effective means of contraception",
"criterion": "contraception use",
"requirements": [
{
"requirement_type": "gender",
"expected_value": "women"
},
{
"requirement_type": "contraception use",
"expected_value": true
}
]
}
]
},
{
"line": "8. Karnofsky Performance status ≥ 60%.",
"criterions": [
{
"exact_snippets": "Karnofsky Performance status ≥ 60%",
"criterion": "Karnofsky Performance status",
"requirements": [
{
"requirement_type": "score",
"expected_value": {
"operator": ">=",
"value": 60,
"unit": "%"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. Known hypersensitivity to folic acid.",
"criterions": [
{
"exact_snippets": "Known hypersensitivity to folic acid",
"criterion": "hypersensitivity to folic acid",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "2. Use of prednisolone more than 10 mg daily.",
"criterions": [
{
"exact_snippets": "Use of prednisolone more than 10 mg daily.",
"criterion": "prednisolone use",
"requirements": [
{
"requirement_type": "dosage",
"expected_value": {
"operator": ">",
"value": 10,
"unit": "mg daily"
}
}
]
}
]
}
],
"miscellaneous_lines": [
{
"line": "Target population: Patients with inoperable, locally advanced, or metastatic renal cell carcinoma.",
"criterions": [
{
"exact_snippets": "inoperable",
"criterion": "operability of renal cell carcinoma",
"requirements": [
{
"requirement_type": "operability",
"expected_value": false
}
]
},
{
"exact_snippets": "locally advanced",
"criterion": "stage of renal cell carcinoma",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "locally advanced"
}
]
},
{
"exact_snippets": "metastatic",
"criterion": "stage of renal cell carcinoma",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "metastatic"
}
]
},
{
"exact_snippets": "renal cell carcinoma",
"criterion": "type of cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}